Get the Stockscreener App
0.00
100.00%
-1.725
Eiger BioPharmaceuticals Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.76 pivot point. If it approaches the $1.38 support level, significant changes may occur.
Previous Close:
$1.725
Open:
$0
24h Volume:
0
Market Cap:
$2.55M
Revenue:
$14.67M
Net Income/Loss:
$-86.65M
P/E Ratio:
0.00
EPS:
-2.18
Net Cash Flow:
$-83.30M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1D Range:
$0.00
$0.00
52W Range:
$0.00
$8.2672
Eiger BioPharmaceuticals Inc Stock (EIGR) Company Profile
Name
Eiger BioPharmaceuticals Inc
Sector
Industry
Phone
650 272 6138
Address
2155 Park Boulevard, Palo Alto, CA
Eiger BioPharmaceuticals Inc Stock (EIGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-19 | Initiated | Citigroup | Buy |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| May-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Jun-21-17 | Resumed | Wedbush | Outperform |
View All
Eiger BioPharmaceuticals Inc Stock (EIGR) Latest News
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
GlobeNewswire Inc.
Dow Falls Over 200 Points; ISM Manufacturing PMI Rises In March
Benzinga
Dow Surges 150 Points; US Jobless Claims Decline Sharply
Benzinga
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Eiger BioPharmaceuticals Inc Stock (EIGR) Financials Data
Eiger BioPharmaceuticals Inc (EIGR) Revenue 2024
EIGR reported a revenue (TTM) of $14.67 million for the quarter ending September 30, 2023, a +3.66% rise year-over-year.
Eiger BioPharmaceuticals Inc (EIGR) Net Income 2024
EIGR net income (TTM) was -$86.65 million for the quarter ending September 30, 2023, a +7.24% increase year-over-year.
Eiger BioPharmaceuticals Inc (EIGR) Cash Flow 2024
EIGR recorded a free cash flow (TTM) of -$83.30 million for the quarter ending September 30, 2023, a -7.10% decrease year-over-year.
Eiger BioPharmaceuticals Inc (EIGR) Earnings per Share 2024
EIGR earnings per share (TTM) was -$59.10 for the quarter ending September 30, 2023, a +18.26% growth year-over-year.
About Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
2.37%
8.04%
Cap:
|
Volume (24h):